SLNO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. SLNO is in a confirmed bearish technical trend (SMA200 > SMA20 > SMA5 with a negatively expanding MACD histogram), and heavy insider selling is a clear near-term overhang. While options positioning is bullish and the stock is oversold enough to bounce, the lack of Intellectia buy signals plus deteriorating momentum means the risk of catching a falling knife is high for an impatient buyer today.
Price/Trend: SLNO is down -3.28% to 39.06 and trading below the pivot (41.891) and slightly below/around the S1 level (39.736), putting it in a weak spot technically with S2 at 38.405 as the next nearby downside level. Momentum: MACD histogram is -0.0964 and negatively expanding, which signals bearish momentum is still strengthening. Moving averages: Bearish alignment (SMA_200 > SMA_20 > SMA_5) confirms a downtrend rather than a simple pullback. RSI: RSI_6 at ~20 is effectively oversold; this increases the odds of a short-term rebound, but oversold can persist in strong downtrends. Levels: Resistance is overhead at 41.89 (pivot) then 44.05 (R1). Support sits at ~39.74 (S1) and 38.41 (S2). Quant pattern read: Similar-pattern projection implies ~+4.16% over the next week and ~+5.23% over the next month, but the next-day edge is slightly negative (-0.22%), consistent with choppy, fragile price action.
Intellectia Proprietary Trading Signals
Analyst support and large upside targets: Recent price target raises to $114 (Wells Fargo) and $120 (H.C. Wainwright) with bullish ratings; these imply major upside from $39 if execution holds.
Product narrative: Commentary highlights Vykat XR revenues beating expectations and long-term $1B+ drug potential in Prader-Willi syndrome per Wells Fargo.
Potential rebound setup: Oversold RSI plus bullish options skew can fuel a reflex rally.
Upcoming event: Earnings scheduled for 2026-02-26 (after hours) can act as a catalyst if revenue/starts or guidance surprise positively.
Strong insider selling: Insider selling flagged as increasing ~1314% over the last month, a meaningful negative signal for near-term confidence/supply.
Bearish technical regime: Downtrend confirmed by moving averages and a negatively expanding MACD; rallies may be sold.
Earnings/event risk ahead: With earnings on 2026-02-26, any disappointment on patient starts, discontinuation rates, or forward outlook could extend the drawdown.
High volatility profile: Historical volatility is very high (>100), consistent with sharp adverse moves when momentum is negative.
No recent news support: No positive news flow in the last week to reverse sentiment immediately.
Latest quarter provided: 2025/Q3. Revenue: $66.018M (reported as 0.00% YoY growth in the snapshot), suggesting growth stalled versus the prior year period. Profitability: Net income fell to $26.013M (-133.95% YoY) and EPS fell to $0.47 (-125.68% YoY). This is a major deterioration versus the year-ago quarter (likely impacted by prior one-time items or cost changes), and it helps explain why the stock can remain weak despite revenue. Margins: Gross margin is extremely high at 98.27% (flat YoY per snapshot), indicating strong unit economics, but the bottom-line drop means operating costs/other items are the current pressure point. Bottom line: The quarter shows mixed quality—excellent gross margin but sharply worse earnings trends, which is not a clean “buy now” setup without a technical reversal.
Recent trend: Net positive. Multiple firms raised price targets recently (Wells Fargo to $114 from $106; H.C. Wainwright to $120 from $110) while maintaining bullish ratings (Overweight/Buy). Wolfe initiated Outperform with a $75 target earlier, noting safety concerns may be overblown and utilization favorable. Wall Street pros: (1) Revenue outperformance vs some expectations; (2) strong long-term product thesis (Vykat XR $1B+ potential); (3) current share price seen as a discount to free-cash-flow potential by Wells Fargo. Wall Street cons: (1) volatility expected around competitor data and patient start trends; (2) management must deliver steady patient start forms; (3) recent weakness tied to slowing new patient starts quarter-over-quarter.
